Giulia Veronesi1, Patrick Maisonneuve2, Lorenzo Spaggiari3, Cristiano Rampinelli4, Alessandro Pardolesi5, Raffaella Bertolotti5, Niccolò Filippi5, Massimo Bellomi6. 1. Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy. Electronic address: giulia.veronesi@ieo.it. 2. Departments of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. 3. Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Milan, Italy. 4. Department of Radiology, European Institute of Oncology, Milan, Italy. 5. Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy. 6. School of Medicine, University of Milan, Milan, Italy; Department of Radiology, European Institute of Oncology, Milan, Italy.
Abstract
INTRODUCTION: Low-dose computed tomography (LD-CT) screening can reduce lung cancer mortality; however, it is essential to improve nodule management protocols. We analyze the performance of the diagnostic protocol of the Continuous Observation of SMOking Subjects single-center screening study, after long-term follow-up. METHODS: Between 2004 and 2005, 5203 asymptomatic high-risk individuals (≥20 pack-years, aged 50 years or older) were enrolled to undergo annual LD-CT for 5 years. Nodules 5 mm or smaller underwent repeat LD-CT a year later. Nodules larger than 5.0 mm and 8.0 mm or smaller received LD-CT 3 to 6 months later. Nodules larger than 8.0 mm or growing underwent CT-positron emission tomography. True positives were any stage prevalent lung cancer, progressing nodules diagnosed at stage 1, localized multifocal cancer, or new nodules diagnosed at any stage. False negatives were progressing nodules diagnosed at stage >1. False positives were benign nodules resected surgically. RESULTS: Compliance was 79% over 5 years; 175 primary lung cancers were detected (0.76% per year), 136 (77.7%) were N0M0 and three were interval cancers. Eleven second primary lung cancers were diagnosed. Resectability was 87.4%; postoperative mortality 0.6%. Recall was 6.4% overall, 10.1% at baseline. False negatives were 14 of 175 (8%). Protocol sensitivity was 158 of 175 (90%); specificity 4994 of 5028 (99.4%); positive predictive value was 158 of 187 (84.5%); and negative predictive value was 4994 of 5016 (99.7%). Twenty-nine of 204 (14.2%) benign lesions were diagnosed surgically. Five-year overall and cancer-specific survival were 78% (95% confidence interval, 72-84) and 82% (95% confidence interval, 76%-88%) respectively. CONCLUSIONS: The performance of the CT protocol was satisfactory with an acceptable number of benign lesions biopsied surgically, low recall rate, and good oncological outcomes. However, interval and advanced cancers, and misdiagnoses, need to be reduced, perhaps by risk modeling and use of serum markers.
INTRODUCTION: Low-dose computed tomography (LD-CT) screening can reduce lung cancer mortality; however, it is essential to improve nodule management protocols. We analyze the performance of the diagnostic protocol of the Continuous Observation of SMOking Subjects single-center screening study, after long-term follow-up. METHODS: Between 2004 and 2005, 5203 asymptomatic high-risk individuals (≥20 pack-years, aged 50 years or older) were enrolled to undergo annual LD-CT for 5 years. Nodules 5 mm or smaller underwent repeat LD-CT a year later. Nodules larger than 5.0 mm and 8.0 mm or smaller received LD-CT 3 to 6 months later. Nodules larger than 8.0 mm or growing underwent CT-positron emission tomography. True positives were any stage prevalent lung cancer, progressing nodules diagnosed at stage 1, localized multifocal cancer, or new nodules diagnosed at any stage. False negatives were progressing nodules diagnosed at stage >1. False positives were benign nodules resected surgically. RESULTS: Compliance was 79% over 5 years; 175 primary lung cancers were detected (0.76% per year), 136 (77.7%) were N0M0 and three were interval cancers. Eleven second primary lung cancers were diagnosed. Resectability was 87.4%; postoperative mortality 0.6%. Recall was 6.4% overall, 10.1% at baseline. False negatives were 14 of 175 (8%). Protocol sensitivity was 158 of 175 (90%); specificity 4994 of 5028 (99.4%); positive predictive value was 158 of 187 (84.5%); and negative predictive value was 4994 of 5016 (99.7%). Twenty-nine of 204 (14.2%) benign lesions were diagnosed surgically. Five-year overall and cancer-specific survival were 78% (95% confidence interval, 72-84) and 82% (95% confidence interval, 76%-88%) respectively. CONCLUSIONS: The performance of the CT protocol was satisfactory with an acceptable number of benign lesions biopsied surgically, low recall rate, and good oncological outcomes. However, interval and advanced cancers, and misdiagnoses, need to be reduced, perhaps by risk modeling and use of serum markers.
Authors: Adrian Huber; Julia Landau; Lukas Ebner; Yanik Bütikofer; Lars Leidolt; Barbara Brela; Michelle May; Johannes Heverhagen; Andreas Christe Journal: Eur Radiol Date: 2016-01-26 Impact factor: 5.315
Authors: Annemilia Del Ciello; Paola Franchi; Andrea Contegiacomo; Giuseppe Cicchetti; Lorenzo Bonomo; Anna Rita Larici Journal: Diagn Interv Radiol Date: 2017 Mar-Apr Impact factor: 2.630
Authors: Peter Mazzone; Charles A Powell; Douglas Arenberg; Peter Bach; Frank Detterbeck; Michael K Gould; Michael T Jaklitsch; James Jett; David Naidich; Anil Vachani; Renda Soylemez Wiener; Gerard Silvestri Journal: Chest Date: 2015-02 Impact factor: 9.410